

**CMP: INR 99**

**Rating: BUY**

**Target Price: INR 165**

**Stock Info**

BSE	543331
NSE	MOL
Sector	Agrochemicals
Face Value (INR)	1
Equity Capital (INR Cr)	25.4
Mkt Cap (INR Mn)	25,220
52w H/L (INR)	116 / 56
Avg Yearly Vol (in 000')	1,471

**Shareholding Pattern %**


(As on Mar, 2025)

Promoters	48.98
Public & Others	51.02

**Stock Performance (%)**

	1m	6m	12m
MOL	-2.56	5.76	-0.35
Nifty	1.14	28.32	13.30

**MOL Vs Nifty**



**Abhishek Jain**

[abhishek.jain@arihantcapital.com](mailto:abhishek.jain@arihantcapital.com)

022-422548871

**Ayush Chaturvedi**

[ayush.chaturvedi@arihantcapital.com](mailto:ayush.chaturvedi@arihantcapital.com)

022-67114834

**Heli Shah**

[heli.shah@arihantcapital.com](mailto:heli.shah@arihantcapital.com)

Meghmani Organics delivered a robust operating performance this quarter, with EBITDA rising 11x YoY, primarily driven by a 68% YoY increase in Agrochemical revenues. This was supported by a strong ramp-up at the MPP facility, resulting in a favorable product mix and enhanced operating leverage. While the Agrochemicals segment posted stellar results, this was partially offset by continued losses in the Pigments business, which remains impacted by subdued realizations and heightened competition owing to persistent Chinese dumping. Consolidated PAT stood at INR 127 mn, a strong turnaround from a post-tax loss of INR 168 mn in the same quarter last year, despite higher depreciation and finance costs—reflecting the sharp growth in EBITDA to INR 669 mn from INR 59 mn.

**Agrochemicals: Strong Growth Driven by Improved Mix-** Volumes in the Agrochemicals segment grew 6% YoY to 10,600 MT, on the back of increased capacity utilization (now at 78%) and incremental ramp-up in MPP. More importantly, a marked shift in the product mix towards higher-value products drove a 68% YoY revenue increase to INR 4.6 bn (vs. INR 2.7 bn last year). Segment EBIT surged to INR 711 mn, compared to an operating loss of INR 12 mn last year, underscoring the operational turnaround. Going forward, we expect the segment to maintain strong growth, supported by new product launches, expanded market reach, and a healthy registration pipeline. Continued focus on new chemistries and specialty products should further drive margin expansion over the medium term.

**Pigments: Performance Constrained by Chinese Dumping-** The Pigments segment remained under pressure due to persistent Chinese dumping and increased competition from unorganized domestic players, leading to capacity utilization of just 46%. Segment revenue grew 8% YoY to INR 1.5 bn, driven by flattish volume growth (3,700 MT), but weak utilizations and realizations resulted in an operating loss of INR 112 mn.

**TiO2 Business: Positive Outlook Post Anti-Dumping Duty:** Although TiO2 segment utilization remained low in Q1 due to ongoing dumping, management notes early signs of a demand revival following the imposition of anti-dumping duty (ADD) by the MoF (\$460–681/MT on Chinese imports). The benefits—higher domestic demand and improved realizations—are expected to materialize from Q3FY26 as channel inventories normalize. Post-ADD, realizations are likely to increase by 20–25%, supporting profitability improvement in the TiO2 portfolio. The company is also pursuing export opportunities in geographies where ADD on Chinese TiO2 is already in place.

**Valuation & View:** We remain positive on Meghmani Organics, particularly on the back of the Agrochemicals segment's strong performance, with expectations of sustained robust growth driven by new product launches, improved operational leverage from higher utilization, and expansion into key regulated markets. The pigments business should stabilize as channel inventories are absorbed and the impact from Chinese dumping moderates post-ADD. We project a 43% EBITDA CAGR over FY25–28E, underpinned by ~22% revenue CAGR and a 430bps improvement in EBITDA margin to 11.2%, supported by (1) ramp-up in MPP contribution (by ~INR 10 billion), (2) improving Agrochemical margins from a better mix, new launches, and market expansion, and (3) double-digit growth in Nano Urea exports as new registrations and product launches gain traction. **We maintain our "Buy" rating with a target price of INR 165, valuing the company at 15x EV/EBITDA on FY27E EBITDA.**

**Financial Performance**

Particulars (INR Mn)	FY23	FY24	FY25	FY26E	FY27E	FY28E
Revenues	25,526	15,663	20,797	25,889	30,881	37,335
EBITDA	3,410	-203	1,427	2,611	3,237	4,178
EBITDA Margins	13.4%	-1.3%	6.9%	10.1%	10.5%	11.2%
PAT	2,377	-1,060	-106	936	1,540	2,356
EPS	9.3	-4.2	-0.4	3.7	6.1	9.3
P/E	11.2	-25.2	-251.9	28.5	17.3	11.3
EV/EBITDA	9.8	-165.6	23.4	12.5	10.0	16.5

Source: Arihant Research, Company Filings

## Q1FY26 Consolidated Performance

Meghmani Organics (Consolidated)					(INR Mn)
Particulars (INR Mns)	Q1FY26	Q1FY25	YoY	Q4FY25	QoQ
Revenue from operations	6,136	4,139	48%	5,535	11%
COGS	3,785	2,628	44%	3,117	21%
Gross Profit	2,352	1,511	56%	2,417	-3%
Gross Profit Margins	38.3%	36.5%	181bps	43.7%	-536bps
<b>Expenses</b>					
Employee Benefits Expenses	296	278	7%	297	0%
Other Expenses	1,386	1,174	18%	1,466	-5%
<b>EBITDA</b>	<b>669</b>	<b>59</b>	<b>1040%</b>	<b>655</b>	<b>2%</b>
<b>EBITDA Margins</b>	<b>10.9%</b>	<b>1.4%</b>	<b>948bps</b>	<b>11.8%</b>	<b>-93bps</b>
Other Income	166	89	87%	139	19%
EBITDA (incl. OI)	835	148	466%	794	5%
EBITDA Margins	13.6%	3.6%	1004bps	14.3%	-74bps
Depreciation	297	235	26%	295	1%
EBIT	538	-87	-716%	499	8%
EBIT Margins	8.8%	-2.1%	1087bps	9.0%	-25bps
Finance Cost	295	106	178%	193	52%
<b>PBT</b>	<b>243</b>	<b>-193</b>	<b>-226%</b>	<b>305</b>	<b>-20%</b>
Exceptional Items					
Profit Before Tax	243	-193	-226%	305	-20%
Tax Expenses	116	-26	-554%	107	8%
<b>PAT</b>	<b>127</b>	<b>-168</b>	<b>-176%</b>	<b>198</b>	<b>-36%</b>

## Segmental Performance

Particulars (INR Mns)	Q1FY26	Q4FY25	Q1FY25	QoQ	YoY
Pigment	1,507	1,527	1,390	1.27%	8.44%
Agrochemicals	4,579	3,697	2,726	-19.25%	67.96%
Others	135	445	115	229.73%	288.07%

Source: Arianth Research, Company Filings

**Q1FY26 Concall Key Highlights****Segmental Performance****Crop Protection:****Revenue and Margin Expansion**

- Segment EBITDA increased sevenfold to INR 790 mn; EBITDA margin expanded to 17.3%, returning to historical averages amid improved product mix.

**Production and Capacity Utilization**

- Production volume: 10,600 metric tons (+6% YoY).
- Capacity utilization at 78%, with management emphasizing overall annual utilization for new multipurpose plant which delivered strong ramp-up and is expected to drive further growth.

**Volume Outpaced by Value**

- While production volume increased just 6% YoY, revenue growth was significantly higher, underscoring gains from higher-value/lower-volume products and a favorable shift in product mix.

**New Product Pipeline and Growth Visibility**

- Strong focus on specialty/new chemistry introductions since FY18, including products like Cyfluthrin, Beta Cyfluthrin, Ethiprole, Flubendiamide, Flonicamid.
- Newer products seeing traction as registrations occur in key global markets (notably Brazil, US, Argentina, Australia, Africa). A patented combination product (Flonicamid+Fipronil, branded 'Iconic') launched in India with plans for global roll-out.
- Management projects double-digit CAGR in crop protection for the next three years, supported by broadening market reach, new product launches and registration pipeline.

**Titanium Dioxide (TiO2):****Tariff Impact and Recovery Outlook**

- Government imposed anti-dumping duty (\$460–\$681/MT) on Chinese TiO2 effective May 10, 2025 (~INR 40–50/kg), expected to aid domestic industry.
- Channel inventory built up at low prices from China should clear by Q3FY26; pricing and utilization gains anticipated from Q3 onwards.
- Utilization in Q1 low due to dumping pressure; now seeing improvement in demand and realization post-ADD.

**Strategic Market Positioning**

- Domestic customers increasingly prefer local supply; experimental orders underway from larger paint manufacturers who previously prioritized imports.
- Management targets first to stabilize current operations and then potentially expand capacity, but concrete expansion details are deferred to subsequent quarters.

**Pigments:****Steady-State, Margin-Focused Approach**

- Production volume: 3,700 MT (+1% YoY), capacity utilization at 46%.
- Management aims to run the business at optimized levels, with a clear bias toward exports over domestic due to higher realization and competitive intensity from unorganized local players.
- Segment is expected to remain flattish with minor YoY fluctuations (INR 500–600 mn range).

**Crop Nutrition (including Nano Urea):**

**Growth Initiatives and Market Response**

- Nano Urea field activities are ongoing in several international markets; seven product registrations received globally.
- FY25 revenue from Nano Urea at INR 400 mn, management guides for double-digit growth in this vertical in FY26, underpinned by positive domestic and international response.
- Significant expansion of product portfolio (2–3 new products targeted for the year).

**Market and Industry****Agchem Pricing and Demand Trends**

- Global channel inventory in crop protection normalized after two years of overhang; new demand visible but pricing yet to recover sharply.
- Raw material and output prices have steadied; expectation of gradual price uptick as Chinese industry faces margin pressure and capacity rationalization.

**Export Markets and Regulatory Developments**

- US imposing 25% tariffs on Indian agchem exports was a negative surprise (management had expected 10–15%); impact under analysis but India remains at an advantage versus China (total Chinese tariff load is ~55%).
- Company's geographical diversification across 75+ countries mitigates concentration risk.

**Product Registrations and Global Expansion**

- Ongoing push for registrations in regulated and semi-regulated markets, especially Brazil (high entry barrier) — management working towards opening Brazilian subsidiary.
- Management highlighted strong pipeline with several registrations expected annually over the next three to four years.

**Titanium Dioxide Market Potential**

- Demand for TiO<sub>2</sub> remains high in India, with diverse end-use applications (paints, ceramics, rubber, paper, etc.).
- ADD is shifting the competitive balance toward local producers; management confident of significant market potential ahead.

**Capital Allocation****Capex and Debt Management**

- Minimal capex expected for FY26, focused on sweating existing assets.
- Priority on debt repayment; management targets further deleveraging through internal accruals.

**Strategic Outlook****Management Guidance**

- Remains positive on sustaining double-digit growth trajectory in core business areas.
- Strategy anchored in new product launches, operating leverage from improved capacity utilization, and expansion in key regulated markets.
- Long-term prospects underpinned by proprietary technology, diversified portfolio, and wider market presence.

**Financial Performance**

- Standalone total debt: INR 5.62 bn (short-term: INR 3.8 bn; long-term: INR 1.82 bn).
- Consolidated total debt: INR 8.09 bn (short-term: INR 3.99 bn; long-term: INR 4.09 bn).
- INR 380 mn of debt repaid during the quarter, with no major capex planned for FY26; management aims to further reduce gearing.

## Financials

(INR Mn)

## Income statement

Particulars (INR Mn)	FY23	FY24	FY25	FY26E	FY27E	FY28E
Gross Sales	25,526	15,663	20,797	25,889	30,881	37,335
<b>Net Sales</b>	25,526	15,663	20,797	25,889	30,881	37,335
YoY (%)	2.2%	-38.6%	32.8%	24.5%	19.3%	20.9%
<b>Adjusted COGS</b>	<b>15,091</b>	<b>10,231</b>	<b>12,639</b>	<b>15,781</b>	<b>18,701</b>	<b>22,345</b>
YoY (%)	3.8%	-32.2%	23.5%	24.9%	18.5%	19.5%
Employee benefit expenses	1,295	1,159	1,144	1,364	1,627	1,967
<i>Other Expenses</i>	5,730	4,475	5,588	6,133	7,316	8,845
<b>Total Expenditure</b>	<b>22,116</b>	<b>15,866</b>	<b>19,370</b>	<b>23,277</b>	<b>27,644</b>	<b>33,157</b>
<b>EBITDA</b>	<b>3,410</b>	<b>-203</b>	<b>1,427</b>	<b>2,611</b>	<b>3,237</b>	<b>4,178</b>
YoY (%)	-9.9%	-105.9%	840.0%	83.0%	24.0%	29.1%
<b>EBITDA Margin (%)</b>	13.4%	-1.3%	6.9%	10.1%	10.5%	11.2%
Depreciation	771	922	1,081	1,562	1,612	1,659
<b>EBIT</b>	<b>2,640</b>	<b>-1,125</b>	<b>346</b>	<b>1,049</b>	<b>1,625</b>	<b>2,520</b>
EBIT Margin (%)	10.3%	-7.2%	1.7%	4.1%	5.3%	6.7%
Interest Expenses	657	464	690	394	383	373
Non-operating/ Other income	960	377	439	580	692	836
<b>PBT</b>	<b>3,131</b>	<b>-1,212</b>	<b>95</b>	<b>1,235</b>	<b>1,934</b>	<b>2,983</b>
Tax-Total	754	-152	201	299	393	627
<b>Adj. Net Profit</b>	<b>2,377</b>	<b>-1,060</b>	<b>-106</b>	<b>936</b>	<b>1,540</b>	<b>2,356</b>
<b>Reported Profit</b>	<b>2,377</b>	<b>-1,060</b>	<b>-106</b>	<b>936</b>	<b>1,540</b>	<b>2,356</b>
PAT Margin	9.3%	-6.8%	-0.5%	3.6%	5.0%	6.3%
Shares o/s/ paid up equity sh capital	254	254	254	254	254	254
Adj EPS	9.3	-4.2	-0.4	3.7	6.1	9.3

## Balance sheet

Particulars (INR Mn)	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Sources of Funds</b>						
Equity Share Capital	254	254	254	254	254	254
Reserves & Surplus/ Other Equity	16,438	15,023	14,898	15,656	16,942	19,044
<b>Networth</b>	<b>16,692</b>	<b>15,277</b>	<b>15,153</b>	<b>15,910</b>	<b>17,197</b>	<b>19,298</b>
Unsecured Loans/ Borrowings/ Lease Liabilities	8,239	8,368	8,292	7,888	7,671	7,464
Other Liabilities	958	655	833	983	1,192	1,445
<b>Total Liabilities</b>	<b>31,984</b>	<b>30,386</b>	<b>30,854</b>	<b>32,689</b>	<b>34,805</b>	<b>36,941</b>
<b>Total Funds Employed</b>	<b>58,977</b>	<b>56,284</b>	<b>58,043</b>	<b>60,936</b>	<b>65,134</b>	<b>69,317</b>
<b>Application of Funds</b>						
<b>Net Fixed Assets</b>	<b>11,760</b>	<b>11,643</b>	<b>15,804</b>	<b>15,047</b>	<b>15,471</b>	<b>15,856</b>
Capital WIP	3,456	5,086	771	771	771	771
<b>Current assets</b>	<b>14,657</b>	<b>12,116</b>	<b>13,501</b>	<b>16,097</b>	<b>17,788</b>	<b>19,535</b>
Inventory	6,517	5,172	5,990	6,940	7,685	8,209
Days	156	209	161	183	146	146
Debtors	5,234	4,329	5,668	6,997	7,720	7,467
Days	76	111	88	99	91	73
Other Current Assets	1,382	1,369	1,110	1,132	1,154	1,178
Cash and Cash equivalent	311	169	227	478	609	1,652
<b>Current Liabilities/Provisions</b>	<b>10,300</b>	<b>10,621</b>	<b>12,036</b>	<b>12,337</b>	<b>13,132</b>	<b>13,078</b>
Creditors / Trade Payables	4,478	4,919	5,505	6,638	7,187	6,804
Days	84	118	94	100	92	74
Liabilities	1,616	1,149	1,055	1,251	1,540	1,910
<b>Net Current Assets</b>	<b>4,356</b>	<b>1,494</b>	<b>1,465</b>	<b>3,760</b>	<b>4,655</b>	<b>6,457</b>
<b>Total Asset</b>	<b>31,984</b>	<b>30,386</b>	<b>30,854</b>	<b>32,689</b>	<b>34,805</b>	<b>36,941</b>
<b>Total Capital Employed</b>	<b>27,628</b>	<b>28,891</b>	<b>29,389</b>	<b>28,929</b>	<b>30,150</b>	<b>30,484</b>

Source: Arianth Research, Company Filings

## Cash Flow Statement

Particulars (INR Mn)	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Profit before tax</b>	<b>2,377</b>	<b>-1,060</b>	<b>-106</b>	<b>936</b>	<b>1,540</b>	<b>2,356</b>
<b>Adjustments: Add</b>						
Depreciation and amortisation	771	922	1,081	1,562	1,612	1,659
Interest adjustment	-303	87	251	-186	-308	-463
<b>Change in assets and liabilities</b>	<b>2,488</b>	<b>-51</b>	<b>1,100</b>	<b>2,135</b>	<b>2,590</b>	<b>3,297</b>
Inventories	-123	1,345	-818	-950	-745	-524
Trade receivables	194	906	-1,339	-1,329	-723	253
Trade payables	-1,259	442	585	1,133	549	-383
Other Liabilities and provisions	1,171	-333	1,047	-717	384	494
Other Assets	145	27	790	-40	-41	-42
Taxes	-3	-4	3	16	34	41
<b>Net cash from operating activities</b>	<b>1,256</b>	<b>1,984</b>	<b>390</b>	<b>1,342</b>	<b>2,088</b>	<b>3,175</b>
Net Sale/(Purchase) of tangible and intangible assets, Capital work in progress	-4,982	-2,430	-975	-806	-2,036	-2,043
Net Sale/(Purchase) of investments	1,243	1,065	1,551	593	698	840
<b>Net cash (used) in investing activities</b>	<b>-3,796</b>	<b>-1,331</b>	<b>405</b>	<b>-217</b>	<b>-1,342</b>	<b>-1,207</b>
Interest expense	1,413	-692	-1,734	250	-522	-493
Dividend paid	-356	0	-127	-178	-254	-254
Other financing activities	-347	-355	41	-178	-313	-254
<b>Net cash (used) in financing activities</b>	<b>2,754</b>	<b>-777</b>	<b>-686</b>	<b>-780</b>	<b>-566</b>	<b>-536</b>
<b>Closing Balance</b>	<b>326</b>	<b>203</b>	<b>312</b>	<b>657</b>	<b>837</b>	<b>2,270</b>
<b>FCF</b>	<b>-2,082</b>	<b>1,199</b>	<b>-4,821</b>	<b>533</b>	<b>50</b>	<b>1,129</b>
Capex ( % of sales )	3,320	784	300	777	2,000	2,001

## Key Ratios

Particulars	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Solvency Ratios</b>						
Debt / Equity	0.5	0.5	0.5	0.5	0.4	0.4
Net Debt / Equity	0.5	0.5	0.5	0.5	0.4	0.3
Debt / EBITDA	2.4	-41.2	5.8	3.0	2.4	1.8
Current Ratio	2.3	-40.2	5.6	2.8	2.1	1.2
<b>DuPont Analysis</b>						
Sales/Assets	0.8	0.5	0.7	0.8	0.9	1.0
Assets/Equity	1.9	2.0	2.0	2.1	2.0	1.9
RoE	14.2%	-6.9%	-0.7%	5.9%	9.0%	12.2%
<b>Per share ratios</b>						
Reported EPS	9.3	-4.2	-0.4	3.7	6.1	9.3
Dividend per share	1.4	0.0	0.5	0.7	1.0	1.0
BV per share	65.6	60.1	59.6	62.6	67.6	75.9
Cash per Share	1.2	0.7	0.9	1.9	2.4	6.5
Revenue per Share	100.4	61.6	81.8	101.8	121.4	146.8
<b>Profitability ratios</b>						
Net Profit Margin (PAT/Net sales)	12.2%	9.3%	-6.8%	-0.5%	3.6%	5.0%
Gross Profit / Net Sales	40.9%	34.7%	39.2%	39.0%	39.4%	40.1%
EBITDA / Net Sales	13.4%	-1.3%	6.9%	10.1%	10.5%	11.2%
EBIT / Net Sales	10.3%	-7.2%	1.7%	4.1%	5.3%	6.7%
ROCE (%)	12.2%	-5.7%	1.8%	5.2%	7.5%	10.6%
<b>Activity ratios</b>						
Inventory Days	156.1	208.5	161.2	182.5	146.0	146.0
Debtor Days	76.2	111.4	87.7	98.6	91.3	73.0
Creditor Days	83.8	118.1	94.2	100.0	92.4	73.7
<b>Leverage ratios</b>						
Interest coverage	4.0	-2.4	0.5	2.7	4.2	6.8
Debt / Asset	0.3	0.3	0.3	0.2	0.2	0.2
<b>Valuation ratios</b>						
EV / EBITDA	9.8	-165.6	23.4	12.5	10.0	7.3
PE (x)	10.7	-24.0	-239.9	27.2	16.5	10.8

Source: Arian Research, Company Filings

**Arihant Research Desk**Email: [instresearch@arihantcapital.com](mailto:instresearch@arihantcapital.com)

Tel. : 022-42254800

Head Office	Registered Office
#1011, Solitaire Corporate Park Building No. 10, 1 <sup>st</sup> Floor Andheri Ghatkopar Link Road Chakala, Andheri (E) Mumbai – 400093 Tel: (91-22) 42254800	6 Lad Colony, Y.N. Road, Indore - 452003, (M.P.) Tel: (91-731) 4217100/101 CIN: L66120MP1992PLC007182

Stock Rating Scale	Absolute Return
BUY	>20%
ACCUMULATE	12% to 20%
HOLD	5% to 12%
NEUTRAL	-5% to 5%
REDUCE	-5% to -12%
SELL	<-12%

Research Analyst Registration No.	Contact	Website	Email Id
INH000002764	SMS: 'Arihant' to 56677	<a href="http://www.arihantcapital.com">www.arihantcapital.com</a>	<a href="mailto:instresearch@arihantcapital.com">instresearch@arihantcapital.com</a>

**Arihant Capital Markets Ltd.**

1011, Solitaire Corporate park, Building No. 10, 1st Floor,  
Andheri Ghatkopar Link Road, Chakala, Andheri (E)  
Tel. 022-42254800

**Disclaimer:** This disclosure statement is provided in compliance with the SEBI Research Analyst Regulations, 2014. Arihant Capital Markets Limited (ACML) is a registered stockbroker, merchant banker, and research analyst under SEBI, and is also a Point of Presence with the Pension Fund Regulatory and Development Authority (PFRDA). ACML is registered with SEBI with Research Analyst Registration Number INH000002764, Stock Broker Registration Number INZ000180939, and is a Trading Member with NSE, BSE, MCX, NCDEX, and a Depository Participant with CDSL and NSDL.

ACML and its associates may have business relationships, including investment banking, with companies covered by its Investment Research Department. The analysts of ACML, and their associates, are prohibited from holding a financial interest in securities or derivatives of companies they cover, though they may hold stock in the companies they analyze. The recommendations provided by ACML's research team are based on technical and derivative analysis and may differ from fundamental research reports.

ACML confirms that neither it nor its associates have a financial interest or material conflict concerning the companies covered in the research report at the time of publication. Furthermore, ACML, its analysts, and their relatives have no ownership greater than 1% in the subject companies as of the month prior to publication. ACML guarantees that the compensation for its research analysts is not influenced by specific securities or transactions.

ACML affirms that neither the analyst nor the company has served as an officer, director, employee, or engaged in market-making activities for any of the subject companies. Additionally, the research report does not reflect any conflict of interest and is not influenced by specific recommendations made. Neither ACML nor its analysts have received compensation for investment banking or brokerage services from the subject companies in the last 12 months.

The views expressed in this report are those of the analysts and are independent of the proprietary trading desk of ACML, which operates separately to maintain an unbiased stance. Analysts comply with SEBI Regulations when offering recommendations or opinions through public media. The report is intended for informational purposes only and is not an offer or solicitation for the purchase or sale of securities.

This report, which is confidential, may not be reproduced or shared without written consent from ACML. It is based on publicly available data believed to be reliable but has not been independently verified, and no guarantees are made about its accuracy. All opinions and information contained in the report are subject to change without notice. ACML disclaims liability for any losses resulting from reliance on this report. The report does not constitute an offer to buy or sell securities, and ACML is not responsible for the risks involved in investments. ACML and its affiliates may have positions in the securities discussed or hold other financial interests in them.

The distribution of this report in certain jurisdictions may be restricted by law, and the report is not intended for distribution where it would violate local laws. Investors are advised to consider their financial position, risk tolerance, and investment objectives before engaging in transactions, particularly in high-risk financial products such as derivatives.

ACML reserves the right to modify this disclosure statement without prior notice. The report has been prepared using publicly available information and internally developed data, though ACML does not guarantee its completeness or accuracy. Historical price data for securities can be accessed via official exchanges like NSE or BSE. ACML and its affiliates may conduct proprietary transactions or investment banking services for the companies mentioned in this report. In compliance with SEBI regulations, ACML maintains comprehensive records of research reports, recommendations, and the rationale for those recommendations, which are preserved for at least five years. An annual compliance audit is conducted by a member of the ICAI or ICSI to ensure adherence to applicable regulations. This report is issued in accordance with applicable SEBI regulations and does not guarantee future performance or returns.

**Arihant Capital Markets Ltd.**

1011, Solitaire Corporate park, Building No. 10, 1st Floor,  
Andheri Ghatkopar Link Road, Chakala, Andheri (E)  
Tel. 022-42254800